Chemical Structure : HH2853
CAS No.:
2202678-05-3
HH2853
(HH-2853, (S)-HH2853)
Catalog No.: PC-24527Not For Human Use, Lab Use Only.
HH2853 is a novel potent dual EZH1/2 inhibitor that effectively inhibit the catalytic activity of wild-type EZH2 and mutated forms (A677G, Y641F, Y641N, and Y641C) with IC50 of 3.75, 2.21, 2.65, and 2.62 nM respectively, synchronously suppresses EZH1 activity with IC50 of 9.26 nM.
Bulk size, bulk discount!
Welcome credit card payment!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Purity & Documentation Purity:
>98% (HPLC)
Biological Activity
HH2853 is a novel potent dual EZH1/2 inhibitor that effectively inhibit the catalytic activity of wild-type EZH2 and mutated forms (A677G, Y641F, Y641N, and Y641C) with IC50 of 3.75, 2.21, 2.65, and 2.62 nM respectively, synchronously suppresses EZH1 activity with IC50 of 9.26 nM.
HH2853 increases H3K27 acetylation in insensitive DLBCL cells.
HH2853 has the same or a slightly stronger inhibitory effect on cancer cells proliferation than EPZ-6438 against a panel of 24 cell lines expressing EZH2 mutations or wild type.
HH2853 exhibits superior anti-tumor efficacy in several tumor xenograft models compared with FDA-approved EZH2 selective inhibitor EPZ-6438 at a comparable dose level.
HH2853 also shows weak anti-tumor activity against EZH2 wild type (EZH2-WT) DLBCL cells in vitro and in vivo.
Physicochemical Properties
|
M.Wt
|
611.67
|
|
Formula
|
C31H36F3N7O3
|
|
Appearance
|
Solid
|
|
CAS No.
|
|
|
Storage
|
- Solide Powder
-
-20°C 12 Months; 4°C 6 Months
|
- In Solvent
-
-80°C 6 Months; -20°C 6 Months
|
|
Shipping
|
|
|
Solubility
|
10 mM in DMSO
|
|
Chemical Name/SMILES
|
(S)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-methyl-1-(6-methylpyridazin-3-yl)-5-(1-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)ethyl)indolizine-7-carboxamide
|
References
1. Yu L, et al. Acta Pharmacol Sin. 2023 Oct;44(10):2113-2124.
2. Chen XX, et al. Abstract 5436: HH2853 is a selective small molecular dual inhibitor of EZH1/2 with potent anti-tumor activities. Cancer Res. 2022;82:5436.
Contact Us
sales@probechem.com
